6-羟基-3-碘-甲基吡啶 | 927870-76-6

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-羟基-3-碘-甲基吡啶
• 中文别名: 2-羟基-5-碘-6-甲基吡啶；6-羟基-3-碘-2-甲基吡啶
• 英文名称: 5-Iodo-6-methylpyridin-2(1H)-one
• 英文别名: 5-iodo-6-methyl-1H-pyridin-2-one
• CAS: 927870-76-6
• 化学式: C₆H₆INO
• mdl: MFCD09037468
• 分子量: 235.024
• InChiKey: UFZSHCNPDKACCS-UHFFFAOYSA-N

物化性质

• 熔点：
  152°C
• 沸点：
  311.6±35.0 °C(Predicted)
• 密度：
  1.94±0.1 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为产物：
  描述：

  2-羟基-6-甲基吡啶 在 碘 、 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 生成 6-羟基-3-碘-甲基吡啶 、 3,5-二碘-6-甲基-2(1H)-吡啶酮 、 3-iodo-6-methylpyridin-2-ol
  参考文献：
  名称：

  Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands

  摘要：

  A novel series of 2-anilino-3-phenylsulfonyl-6-methylpyridines was synthesized and evaluated as corticotropin-releasing factor receptor ligands. Structure-activity relationship studies focused primarily on optimization of the 3-phenylsulfonyl group. Compounds within this series were identified which showed potent binding affinity for the CRFI receptor. Selected compounds were examined in a rat pharmacokinetic study and were found to have oral bioavailabilities ranging from 16 to 35%. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.097

文献信息

• [EN] PHYSICAL FORM OF A SGR MODULATOR<br/>[FR] FORME PHYSIQUE D'UN MODULATEUR SÉLECTIF DU RÉCEPTEUR DES GLUCOCORTICOÏDES
  申请人：ASTRAZENECA AB

  公开号：WO2017162747A1

  公开（公告）日：2017-09-28

  A crystalline form of 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxo-1,6- dihydropyridin-3-yl)-1H-indazol-5-yl]oxy}-1-phenylbutan-2-yl]propanamide (form C), pharmaceutical compositions containing it and its use in therapy.

  2,2-二氟-N-[(1R,2S)-3-甲基-1-[1-(1-甲基-6-氧代-1,6-二氢吡啶-3-基)-1H-吲唑-5-基]氧基}-1-苯基丁-2-基]丙酰胺（C型晶体形态），含有它的制药组合物以及它在治疗中的用途。
• Indazole derivatives as αv integrin antagonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10745384B2

  公开（公告）日：2020-08-18

  The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(Ia)或(Ib)化合物：或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量如本文所定义。这些化合物是含αV整合素的拮抗剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与含αV整合素失调有关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• PHYSICAL FORM OF A SGR MODULATOR
  申请人：Astrazeneca AB

  公开号：EP3433248A1

  公开（公告）日：2019-01-30
• INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190256496A1

  公开（公告）日：2019-08-22

  The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.